All News

Incretin-mimetics may have even broader application against disease than scientists can predict, but the risks are real, too, according to a study of 2 million.

The approval of esketamine follows an FDA Priority Review and is based on data showing that esketamine alone demonstrated rapid and superior improvement in depressive symptoms compared with placebo.

Findings of the study support the AHS 2024 statement supporting CGRP inhibitors as first-line options and calling for reducing overall costs of migraine treatment.

The properties of ASC30 may allow the small molecule GLP-1 RA to be formulated as a monthly injection and daily oral tablet, Ascletis said.

The key factors predicting stable response to tralokinumab every 4 weeks (vs every 2 weeks) were IGA 0/1 and EASI-75, according to a small post hoc analysis.

Findings showed that improved skin clearance and reduced anxiety and depression significantly influenced perceived patient benefit.

The novel therapeutic demonstrated a strong safety profile and showed efficacy in reducing symptoms during the early stages of treatment.

Agency review determined the pouches to be less harmful to health than cigarettes and an aid to smoking cessation but did not declare the products "safe."

Your daily dose of the clinical news you may have missed.

Caissa Troutman, MD, shares 3 key strategies for managing hypertension in patients with obesity in primary care.

An expert discussion with JoAnn Pinkerton, MD, national lead for the OASIS clinical trial program of elinzanetant for moderate-to-severe VMS.

Annual colorectal cancer screening with FIT was the most cost-effective strategy among patients with low adherence, researchers reported.

Price negotiations, effective in 2027, cover drugs for diabetes, cancer, COPD, and more, aiming for substantial Medicare savings.

The 20.7% weight loss with the high-dose of semaglutide bested the mean reduction of 17.5% seen with semaglutide 2.4 mg, according to Novo Nordisk.

Your daily dose of the clinical news you may have missed.

The DEA action includes 3 new telehealth rules that make permanent several flexibilities enacted during the pandemic and also establish new protections for patients.

Mineralys Therapeutics also expects topline data from its phase 2 study of lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension when used as an add-on therapy.

The effective approach to identifying risk for the disruptive cognitive issues holds promise for development of early intervention to mitigate decline.